SECRETIN INFUSION THERAPY FOR AUTISM

Description: Infusion of the pancreatic hormone secretin is an accepted approach for assessing pancreatic function. In this context, it is performed as part of the gastrointestinal evaluation. Recent anecdotal information has reported a link between the infusion of secretin and improvements in certain symptoms associated with autism (e.g., social behavior, language skills, or communication).

Policy: Secretin infusion therapy for treatment of autism is considered INVESTIGATIVE due to the lack of any scientific evidence to justify its use. Secretin infusion therapy for the treatment of all mental and substance-related disorders is considered INVESTIGATIVE.

Coverage: Blue Cross and Blue Shield of Minnesota medical policies apply generally to all Blue Cross and Blue Plus plans and products. Benefit plans vary in coverage and some plans may not provide coverage for certain services addressed in the medical policies.

Medicaid products and some self-insured plans may have additional policies and prior authorization requirements. Receipt of benefits is subject to all terms and conditions of the member’s summary plan description (SPD). As applicable, review the provisions relating to a specific coverage determination, including exclusions and limitations. Blue Cross reserves the right to revise, update and/or add to its medical policies at any time without notice.

For Medicare NCD and/or Medicare LCD, please consult CMS or National Government Services websites.

Refer to the Pre-Certification/Pre-Authorization section of the Medical Behavioral Health Policy Manual for the full list of services, procedures, prescription drugs, and medical devices that require Pre-certification/Pre-Authorization. Note that services with specific coverage criteria may be reviewed retrospectively to determine if
criteria are being met. Retrospective denial of claims may result if criteria are not met.

**Coding:**

The following codes are included below for informational purposes only, and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.

**HCPCS:**

J2850 Injection, secretin, synthetic, human, 1 microgram

**Policy History:**

Developed April 14, 1999

**Most recent history:**
Reviewed September 8, 2010
Reviewed September 14, 2011
Reviewed September 12, 2012
Reviewed September 11, 2013

**Cross Reference:**

Autism Spectrum Disorders: Assessment, X-43

Current Procedural Terminology (CPT®) is copyright 2013 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values, or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.

Copyright 2014 Blue Cross Blue Shield of Minnesota.